ganirelix acetate

ganirelix acetate

Orgalutran (CA) (UK)

Pharmacologic class: Gonadotropin-releasing hormone (GnRH) antagonist

Therapeutic class: Sex hormone

Pregnancy risk category X


Competitively blocks GnRH receptors on pituitary gonadotroph, suppressing secretion of gonadotropin and luteinizing hormone (LH) and thereby preventing ovulation


Prefilled syringe: 250 mcg/0.5 ml

Indications and dosages

To inhibit premature LH surges during controlled ovarian hyperstimulation

Adult women: 250 mcg subcutaneously daily during early to midfollicular phase


• Hypersensitivity to drug, its components, GnRH, or GnRH analogs

• Known or suspected pregnancy


Use cautiously in:

• GnRH sensitivity

• latex sensitivity (packaging contains natural rubber latex)

• breastfeeding patients.


Know that pregnancy must be excluded before therapy begins.

• Inject into abdomen (around navel) or upper thigh.

• Be aware that drug is given with follicle-stimulating hormone (FSH). After starting FSH on day 2 or 3 of menstrual cycle, patient receives ganirelix on morning of day 7 or 8 and continues this drug until adequate follicular response occurs. Then human chorionic gonadotropin is given and FSH and ganirelix are discontinued.

Adverse reactions

CNS: headache

GI: nausea, abdominal pain of GI tract origin

GU: abdominal pain of gynecologic origin, vaginal bleeding, ovarian hyperstimulation syndrome

Other: injection site reaction, fetal death


Drug-diagnostic tests. Hematocrit, total bilirubin: decreased values

Neutrophils: altered count (8.3/mm3 or greater)

Patient monitoring

Monitor patient for adverse effects, especially ovarian hyperstimulation.

• Monitor total bilirubin level and CBC with white cell differential.

Patient teaching

• Inform patient about possible adverse reactions.

• Teach patient about duration of treatment and required monitoring procedures.

Urge patient to tell prescriber if she is pregnant before starting drug.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


An injectable synthetic decapeptide gonadotropin-releasing hormone (GnRH) antagonist used to inhibit premature LH surges in women undergoing controlled ovarian hyperstimulation in assisted reproduction.

Adverse effects
Gynaecologic pain, foetal death, headache, ovarian hyperstimulation syndrome, vaginal bleeding.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
received final FDA approval for its Abbreviated New Drug Application (ANDA) for a generic version of Organon's Ganirelix Acetate Injection, 250 mcg/0.5 mL.
- Switzerland-based biopharmaceutical company Ferring Pharmaceuticals has inked an exclusive agreement to acquire the US commercialisation rights for a generic version of Ganirelix Acetate Injection from Sun Pharmaceutical Industries Ltd.
On November 30, 2018, Sun Pharma received final approval from the US FDA for its Abbreviated New Drug Application for generic version of Ganirelix Acetate Injection, 250 mcg/0.5 mL.
Food and Drug Administration's approval of ANTAGON (ganirelix acetate) Injection, indicated for inhibiting premature leutenizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.